Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY 16 APIs Including Aricept, Lyrica to Be Re-Priced for Market Expansion
January 25, 2012
-
BUSINESS Mochida President Hopes to Ease Impact of Next NHI Price Revision with New Drugs
January 24, 2012
-
BUSINESS Growell President Takada Says Ready for Legal Action on Stoppage of “Dispensing Point” System
January 23, 2012
-
REGULATORY PMDA to Introduce Direct ADR Reporting System for Patients on Trial Basis
January 20, 2012
-
BUSINESS Takeda President Hasegawa Envisions Japanese National as Successor
January 19, 2012
-
BUSINESS Nexium Dominates Top 2 Rankings in HP Market 2 Months in a Row: RepTrack Dec. Survey
January 18, 2012
-
ORGANIZATION JPWA, NPhA Hold Talks for Distribution Improvement
January 18, 2012
-
REGULATORY US Industry Opinion Divided on Japan’s Participation in TPP Talks
January 17, 2012
-
REGULATORY MHLW Proposes New Fee for Medical Management of Treatment-Resistant Schizophrenia
January 16, 2012
-
ORGANIZATION JGA President Sawai Says Members United to Provide Stable Drug Supplies to Meet Boosted Demand
January 13, 2012
-
ORGANIZATION JPWA President Bessho Expresses Resolve for Distribution Improvement
January 12, 2012
-
BUSINESS Kyowa Hakko Kirin to Develop Expert MRs to Boost Cancer Field
January 11, 2012
-
BUSINESS Bayer Yakuhin President Guth Says Marketing Success of 2 Strategic Products Key Focus
January 10, 2012
-
BUSINESS AZ to Utilize E-detailing, Optimize According to Product
January 6, 2012
-
ORGANIZATION FPMAJ Chairman Pledges Further Efforts for Permanent Introduction of Premium, Caution Towards Additional Price Cuts Becoming Rule
January 5, 2012
-
ORGANIZATION New Year’s Message: On behalf of the JPMA, I would like to express our best wishes for a Happy New Year as we see the start of 2012.
January 5, 2012
-
BUSINESS Aricept Overtakes Blopress to Take Top Spot in Domestic Drug Sales
December 28, 2011
-
REGULATORY Additional NHI Price Cuts Decided: ¥22.5 Billion for Long-Listed Drugs, ¥2.5 Billion for Generics
December 27, 2011
-
REGULATORY PFSB Draft Budget Includes ¥2.1 Bil. to Improve Review, Safety Measures
December 27, 2011
-
BUSINESS Chugai to Participate in Multinational Study of Avastin in Breast Cancer
December 27, 2011
ページ
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…